Cooperman’s Omega Capital Hurt By Sunedison In Q3Mark Melin
Leon Cooperman’s Omega Capital partners, which was long healthcare roll-up Allergan as one of the top holding through the turbulent August to October period, found its most profitable strategy component to be an option selling strategy, recent investor slides reviewed by ValueWalk reveal.
What also stands out is the fund’s category exposures. Omega’s short equities / futures / options category, expressed as the “short” side of the long short strategy, experienced an odd performance ratio disparity during the stock market crisis that might have . . .
This content is exclusively for paying members. Access all of our content on including years of timeless investment news and in depth analysis for only a few dollars a month by signing up here while also supporting quality content and journalism, or learn more about our premium content here
If you are subscribed and having an account error please clear cache and then cookies if that does not work email email@example.com and we will get back to you as quick as humanly possible